Related Experiment Video
Updated: Apr 30, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Palivizumab compliance by infants in Puerto Rico during the 2009-2010 respiratory syncytial virus season
Israel Matías1, Inés García-García, Lourdes García-Fragoso
1Department of Pediatrics, Neonatology Section, UPR School of Medicine, PO BOX 365067, San Juan, PR, 00936-5067, USA, israel.matias@upr.edu.
Insights
Palivizumab prophylaxis compliance for infants against respiratory syncytial virus (RSV) was low in Puerto Rico. Key barriers included insurance denials and parental factors, necessitating improved education and strategies.
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Respiratory syncytial virus (RSV) is a major cause of infant bronchiolitis and pneumonia.
- Palivizumab is a monoclonal antibody used for RSV prophylaxis in high-risk infants.
- Understanding prophylaxis compliance is crucial for effective disease prevention.
Purpose of the Study:
- To assess the compliance rate of palivizumab prophylaxis for eligible infants in Puerto Rico.
- To identify barriers to palivizumab prophylaxis adherence.
- To inform strategies for improving RSV prevention in vulnerable infant populations.
Main Methods:
- Retrospective study of 868 infants during the 2009-2010 RSV season in Puerto Rico.
- Data analysis included infant demographics, gestational age, birth weight, and prophylaxis receipt.
- Reasons for noncompliance were documented and analyzed.
Main Results:
- Only 74% of infants with indications received palivizumab prophylaxis.
- Major barriers included medical insurance non-approval (53%), parental unavailability (31%), and infant sickness (11%).
- Infants with government insurance faced higher denial rates and fewer doses.
Conclusions:
- Palivizumab prophylaxis compliance in Puerto Rico is suboptimal.
- Addressing insurance barriers and enhancing parental engagement are critical.
- Improved physician awareness and targeted strategies are needed to increase RSV prophylaxis adherence.
Abstract:
Respiratory syncytial virus (RSV) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants. We assessed palivizumab prophylaxis compliance for infants in Puerto Rico. We retrospectively studied data from 868 infants (409 females, 459 males) during the 2009-2010 RSV season. The infants had a mean gestational age of 33 weeks (range 23-41) and a mean birth weight of 1,767 g (range 509-4,120). Only 74 % of the infants with indications received prophylaxis. The main reasons for noncompliance were non-approval by the medical insurance (53 %), parents' unavailability (31 %), and infant sickness (11 %). Infants with the government medical insurance were more likely to be denied prophylaxis and to receive fewer doses. Parents need to be educated on the importance of RSV prophylaxis. Physicians should be aware that many infants are not being dosed appropriately and that strategies need to be established to improve compliance.
More Related Videos
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Influenza
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Respiratory Volumes and Capacities I

